Two senators from either side of the aisle introduced a bill this week that is aimed squarely at the patent strategies that are used to block biosimilars from coming to market.
Two senators from either side of the aisle introduced a bill this week that is aimed squarely at the patent strategies that are used to block biosimilars from coming to market.
Senator Susan Collins, R-Maine, and Senator Tim Kaine, D-Virginia, introduced the Biologic Patent Transparency Act, which would require companies to publicly disclose the patents that protect their originator biologics, thus making it easier for competitors to evaluate and plan for the development of biosimilars.
It is co-sponsored by Senators Rob Portman, R-Ohio; Jeanne Shaheen, D-New Hampshire; Mike Braun, R-Indiana; and Debbie Stabenow, D-Michigan.
If the transparency bill becomes law, it would codify the publication of FDA’s Purple Book as a single, searchable list, as well as require additional information:
In addition, it would limit the enforceability of late-filed patents by the biologic manufacturer when a biosimilar application has already been filed with the FDA, such as those used by AbbVie to protect its brand name adalimumab (Humira) from competition.
“The past century could be termed the Age of Miracle Drugs. Today, however, we might define a ‘miracle drug’ as one that has not doubled in price since the last refill,” Collins said in a statement. “We must provide drug makers with the ability to recoup their investments, but at the same time, we cannot be blind to the costs of these drugs, nor to cases where patent laws are manipulated to preserve monopolies. This legislation is an important step to stop the patent gaming that blocks consumers from accessing lower-cost biologics.”
“Biologic medicines can be life-changing for many patients, but we must do more to promote competition in the market to ensure patients can access and afford them. Our bill sheds light on the ways patents can be used to deter competition and encourages manufacturers to obtain key patents earlier, which will help bring new treatments to patients faster,” said Kaine.
Biologic manufacturers often seek to protect their products by using dozens or hundreds of patent thickets; even if some of the patents are later found to be invalid or unenforceable by the court or the Patent Trial and Appeal Board, expensive patent litigation can deter competitors from moving forward with developing biosimilars.
In an email to The Center for Biosimilars® , Michael A. Carrier, JD, distinguished professor at Rutgers Law School, noted that the issue of patent thickets, which keep generic and biologic competition out of the marketplace, has been receiving a lot of scrutiny in Congress, “so it’s possible this becomes law.”
For instance, in January, during a House Committee on Oversight and Reform hearing into drug prices, Aaron S. Kesselheim, MD, JD, MPH, of Harvard Medical School and Brigham and Women’s Hospital, testified that patent exclusivities constitute government-granted monopolies on drugs and pointed to the example of Humira’s “patent thicket” that has forestalled US competition until 2023.
“The restriction of enforcement of patents issued after a biosimilar has been submitted to FDA could encourage the earlier filing of patents and significantly open the thicket, facilitating biosimilars’ entry into the market,” wrote Carrier.
BioRationality: EMA Accepts Waiver of Clinical Efficacy Testing of Biosimilars
April 21st 2025Sarfaraz K. Niazi, PhD, shares his latest citizen's petition to the FDA, calling on the agency to waive clinical efficacy testing in response to the European Medicines Agency's (EMA) efforts towards the same goal.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
How State Substitution Laws Shape Insulin Biosimilar Adoption
April 15th 2025States with fewer restrictions on biosimilar substitution tend to see higher uptake of interchangeable insulin glargine, showing how even small policy details can significantly influence biosimilar adoption and expand access to more affordable insulin.
Biosimilars Policy Roundup for September 2024—Podcast Edition
October 6th 2024On this episode of Not So Different, we discuss the FDA's approval of a new biosimilar for treating retinal conditions, which took place in September 2024 alongside other major industry developments, including ongoing legal disputes and broader trends in market dynamics and regulatory challenges.
BioRationality: Commemorating the 15th Anniversary of the BPCIA
April 8th 2025Affirming that analytical characterization is often sufficient for biosimilar approval, minimizing unnecessary clinical testing, and enhancing FDA-led education to counter stakeholder misconceptions are key recommendations put forth in this opinion piece by Sarfaraz K. Niazi, PhD.